Concepedia

G. B. MULLEN

GB

Statistics

Publications

21

Citations

1.1K

H-Index

16

Active since

1978

Affiliations

AstraZeneca (United States)(Current)

University of Rochester

Gradient Lens Corporation (United States)

G. B. MULLEN is an author at AstraZeneca (United States) specializing in medicinal chemistry, pharmacology, and drug discovery.

Publications per year

1978–2011

21

Publications

21

The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective α7 nicotinic receptor partial agonist

John E. Macor, David Gurley, Thomas H. Lanthorn et al. · Bioorganic & Medicinal Chemistry Letters · 2001 · 159 citations · Full text

, , +15

Synthesis in the tropane class of alkaloids. Pseudotropine and dl-cocaine

Joseph J. Tufariello, G. B. MULLEN, John J. Tegeler et al. · Journal of the American Chemical Society · 1979 · 144 citations

, , +9

Pyrrolamide DNA Gyrase Inhibitors: Fragment-Based Nuclear Magnetic Resonance Screening To Identify Antibacterial Agents

Ann E. Eakin, Oluyinka Green, Neil J. Hales et al. · Antimicrobial Agents and Chemotherapy · 2011 · 134 citations

, , +17

(−)-Spiro[1-azabicyclo[2.2.2]octane-3,5‘-oxazolidin-2‘-one], a Conformationally Restricted Analogue of Acetylcholine, Is a Highly Selective Full Agonist at the α7 Nicotinic Acetylcholine Receptor

G. B. MULLEN, James Napier, Michael Balestra et al. · Journal of Medicinal Chemistry · 2000 · 132 citations · Full text

, , +17

Pyrrolamide DNA gyrase inhibitors: Optimization of antibacterial activity and efficacy

Brian Sherer, Kenneth G. Hull, Oluyinka Green et al. · Bioorganic & Medicinal Chemistry Letters · 2011 · 121 citations · Full text

, , +14

1–5 of 21